Scientist, Research Pathology @ gRED
Pathology
Dr. Jennifer M. Giltnane, MD
|
|
Give Review
Doctor Jennifer M. Giltnane, MD practices Pathology. She attended Yale University School of Medicine. Yale University School of Medicine is a top medical college. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine Jennifer Giltnane is a published doctor and has 20 publications published. The lastest was: 'Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.'
Publications
- Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
- Inhibition of BMP signaling suppresses metastasis in mammary cancer.
- PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: The missing link supporting a stem cell origin.
- Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
- Analytic variability in immunohistochemistry biomarker studies.
- Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.
- Quantitative, fluorescence-based in-situ assessment of protein expression.
- Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
- Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast c...
- Bimodal population or pathologist artifact?
- High HSP90 expression is associated with decreased survival in breast cancer.
- Gene regulation mediated by calcium signals in T lymphocytes.
- AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
- Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.
- Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.
- Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of A...
- Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative n...
- The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
Schools
Yale University
Doctors Specialties
- Pathology
Accepted Insurances
Education
-
Vanderbilt University -
Yale University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Helpful Reviews
Similar Doctors
|
|
Dr. Robert E. Burnette, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward C. McDonald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fritz Parl, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jonathan R. Oppenheimer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omar Hameed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Candice Frederick, MD
This Doctor is OpenDoctor Recommended.
|